Injected Versions of Cancer Meds Make Life Easier for Patients and Drive Savings for Clinicians. There Is a Backlash Anyway
Shares:
If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv
As is tradition, Merck is out as the first company to talk about 2023 list- and net-price changes across its portfolio. The company dropped its annual Pricing Action Transparency Report